Navigation Links
UC Berkeley Expands Molecular Toxicology Curriculum to Include GeneGo's Platform
Date:1/8/2008

ST. JOSEPH, Mich., Jan. 8 /PRNewswire/ -- GeneGo, Inc., the leading provider of databases, software and services in systems biology, announced today that UC Berkeley will expand the use of its MetaCore/MetaDrug Discovery Platform in their Computational Toxicology course, a required component for Molecular Toxicology majors, and in undergrad honors research programs. The agreement will provide students with chemical structure, network and pathway analysis tools needed to analyze complex omics datasets and to predict and understand the beneficial and potentially harmful effects of chemicals in humans and other species.

"When we designed our Computational Toxicology course a few years ago we anticipated a shift in the future toward 'systems biology' that is, looking at the complex interactions of metabolic, genetic, protein, and cellular elements with the goal of modeling entire systems in relation to chemical stresses," said Dale Johnson, Pharm.D., Ph.D., Adjunct Professor, who designed and teaches the Computational Toxicology course. "The complexity of these chemical/biological interactions resulting from environmental exposures, food sources, or pharmaceutical compounds, highlights our thinking that an overall systems approach will be necessary if relevant advances are to be made in applying computational solutions. GeneGo has presented us with an outstanding platform that continues to grow in functionality each year. We are extremely pleased to be able to utilize MetaCore/MetaDrug as the core part of our coursework."

"We are pleased with the decision of UC Berkeley's Department of Nutritional Sciences and Toxicology to include our tools in its curriculum, which is one of the very best in the world," said Julie Bryant, Vice President of Business Development for GeneGo. "The study of fundamental biology is changing quickly with omics technology and systems level analysis, and these changes affect application fields such as toxicology. UC Berkeley will be educating a new breed of toxicology researchers that are needed for the future success of taking drugs to market."

"Today's drug and chemical safety assessment process increasingly leverages information from many different sources," said Dr. Richard Brennan, GeneGo's Director of Toxicology. "Molecular toxicologists need to be able to put traditional toxicology measurements in the context of chemical information as well as biochemical, gene expression, protein and metabolite data. Industry needs scientists well-versed in complex systems biology data, and in the powerful and flexible analysis tools increasingly used in safety assessment. UC Berkeley is leading the way in providing training in current and emerging technologies, and we are pleased to be able to contribute to this cutting-edge program."

About GeneGo

GeneGo develops systems biology technology for life science research. The original computational MetaDiscovery(TM) platform allows an integration and expert analysis of different kinds of experimental data (mRNA expression, proteomics, metabolomics, microRNA assays and other phenotypic data) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics) within the framework of curated biological pathways and networks. GeneGo's flagship product, MetaCore 4.5(TM), assists pharmaceutical scientists in the areas of target selection and validation, identification of biomarkers for disease states and toxicology. The second product, MetaDrug 4.5(TM) is designed for prediction of human metabolism, toxicity and biological effects for novel small molecules compounds. MetaBase(TM) represents the knowledge base for MetaCore. For more information, please visit the company's web site at http://www.genego.com

MetaCore(TM), MetaBase(TM), MetaDrug(TM), MetaLink(TM), MetaDiscovery(TM), MetaTox(TM) and MetaMiner(TM), 1-2-3 Workflow(TM) are trademarks of GeneGo, Inc.


'/>"/>
SOURCE GeneGo, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Advanced Immune Support Formula Licensed From UC Berkeley Launched
2. Observant LLC Expands Senior Management Team
3. Pearl Therapeutics, Inc. Expands Its Senior Management Team With Top Talent in Clinical Development and Regulatory Affairs
4. HealthTrust Expands Contract With Instrumentation Laboratory for Critical Care Portfolio to Include Consorta
5. CSL Behring Expands Into Middle East Market with Haemate(R) P
6. Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
7. Lucid Expands Support Internationally: Dr. Colin Stahel appointed Director for Asia Pacific Region
8. Siemens Expands the SOMATOM Definition(TM) Line With Worlds First Adaptive CT Scanner
9. VIA Pharmaceuticals Expands Clinical Advisory Board With Leading Experts in Cardiovascular Disease
10. Southern Research Expands Sales and Marketing Agreement with Absorption Systems to Service European Market
11. Imaging Diagnostic Systems Expands Key Patent Coverage
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... TOKYO , June 24, 2016  Regular discussions on ... to take place between the two entities said Poloz. ... in Ottawa , he pointed to the ... and the federal government. ... Poloz said, "Both institutions have common economic goals, why not ...
(Date:6/24/2016)... ... ... While the majority of commercial spectrophotometers and fluorometers use the z-dimension of 8.5 ... end machines that use the more unconventional z-dimension of 20mm. Z-dimension or ... the cuvette holder. , FireflySci has developed several Agilent flow cell product lines ...
(Date:6/23/2016)... Seattle, WA (PRWEB) , ... June 23, 2016 ... ... technology, announces the release of its second eBook, “Clinical Trials Patient Recruitment and ... patient recruitment and retention in this eBook by providing practical tips, tools, and ...
(Date:6/23/2016)... June 23, 2016   Boston Biomedical , ... compounds designed to target cancer stemness pathways, announced ... granted Orphan Drug Designation from the U.S. Food ... gastric cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin ... to inhibit cancer stemness pathways by targeting STAT3, ...
Breaking Biology Technology:
(Date:5/9/2016)... 2016 Elevay is currently known ... freedom for high net worth professionals seeking travel for ... connected world, there is still no substitute for a ... sealing your deal with a firm handshake. This is ... advantage of citizenship via investment programs like those offered ...
(Date:4/26/2016)... 2016 Research and Markets has ... Market 2016-2020"  report to their offering.  , ,     ... The analysts forecast the global multimodal biometrics market ... the period 2016-2020.  Multimodal biometrics is ... as the healthcare, BFSI, transportation, automotive, and government ...
(Date:4/13/2016)...  IMPOWER physicians supporting Medicaid patients in ... standard in telehealth thanks to a new partnership with ... IMPOWER patients can routinely track key health measurements, such ... and, when they opt in, share them with IMPOWER ... local retail location at no cost. By leveraging this ...
Breaking Biology News(10 mins):